Core Viewpoint - The establishment of the Health Management Company by China People's Health Insurance Co., Ltd. marks a significant step towards integrating health management services into the insurance model, aiming to enhance public health and transition from reactive to proactive health management [1][3]. Group 1: Company Development - The Health Management Company is the first specialized health insurance company in China, aligning its development with national strategies and the goals of the China People's Insurance Group [1]. - The company aims to create a new business model that combines insurance, health services, and technology, focusing on a comprehensive health management service system to reduce disease and disability risks [1][5]. - The company has achieved significant progress in high-quality development, demonstrating improved operational efficiency and innovative transformations [1]. Group 2: Health Management Advantages - Health management is identified as a core competitive advantage for the company, with a nationwide ecosystem covering medical, pharmaceutical, rehabilitation, and insurance services [2]. - The health management team has over 450 members and offers a diverse range of 30 service products, supported by a robust digital health service platform [2]. - The company has established partnerships with over 10,000 hospitals and 230,000 pharmacies, providing health management services to over 100 million individuals [2]. Group 3: Strategic Goals - The establishment of the Health Management Company is a key initiative for the China People's Insurance Group's broader health and elderly care ecosystem, transitioning from traditional reimbursement to managed care [3]. - The company aims to develop a new health service guarantee system that integrates prevention, management, and post-care support, contributing to the "Healthy China" initiative [3][4]. - The leadership emphasizes the importance of building a leading service system, upgrading health management services, and supporting the development of the biopharmaceutical industry [4]. Group 4: Future Directions - The company plans to enhance its health management services as a means of risk reduction, focusing on integrating health insurance and management functions [5]. - It aims to create a nationwide self-owned medical health service network and optimize a unified health management platform centered around internet hospitals [5]. - The company is committed to contributing to the aging economy and becoming a collaborative hub for medical institutions, pharmaceutical companies, insurance firms, and technology enterprises [5].

Core Insights - The company expresses gratitude to all employees, retirees, partners, and clients as it approaches the new year of 2026, highlighting the achievements of 2025 as a year of high-quality development and successful completion of the "14th Five-Year Plan" [2][13] Group 1: Achievements and Financial Performance - The company has launched new products and models such as "Kehui Insurance" and "Zhiwei Insurance," contributing to stability in foreign trade, supporting innovation, and enhancing consumer protection [3][14] - The total insurance liability amount during the "14th Five-Year Plan" period reached 13.9 trillion yuan, with total compensation payments of 2 trillion yuan, averaging 1.1 billion yuan per day, showcasing the company's leadership role in the industry [3][14] - The group's premium income has surpassed 730 billion yuan, exceeding the targets set in the "14th Five-Year Plan," with net profits reaching a historical high and significant growth in new business value for life insurance [4][15] Group 2: Reforms and Strategic Initiatives - The company is committed to advancing six reforms to optimize management structures and enhance digital capabilities, focusing on improving employee welfare and addressing key operational challenges [5][16] - The company emphasizes the importance of political integrity and public service in its financial operations, aiming to better serve national economic goals and improve living standards [7][18] - The company is focused on maintaining a correct view of operations, performance, and risk, while optimizing its business layout and enhancing its core competitiveness [8][19] Group 3: Future Outlook - As the company transitions into the "15th Five-Year Plan," it anticipates a robust development trajectory for the insurance industry, positioning itself for a new phase of growth [6][17] - The company aims to strengthen its governance structure and enhance strategic control while responding to grassroots concerns and accelerating reforms in digitalization and resource sharing [9][20]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 中国人民保险集团股份有限公司（"本公司"）于 2025 年 6 月 27 日召开 2024 年度股东会，审议通过《关于修改〈中国人民保险集 团股份有限公司章程〉的议案》，修改后的公司章程（"新版公司章 程"）待国家金融监督管理总局核准后生效。 证券代码：601319 证券简称：中国人保 公告编号：临 2025-044 中国人民保险集团股份有限公司 关于公司章程修改获核准及 不再设立监事会的公告 2025 年 12 月 31 日 近日，本公司收到《国家金融监督管理总局关于中国人民保险集 团股份有限公司修改章程的批复》（金复〔2025〕775 号），新版公 司章程已获国家金融监督管理总局核准并正式生效。新版公司章程全 文请参见上海证券交易所网站（www.sse.com.cn）和本公司网站 （www.picc.com）。 自新版公司章程生效日起，公司不再设立监事会，监事会职权转 由董事会审计委员会行使。李慧琼女士、王亚东先生、何祖望先生同 步退任本公司监事。 李慧琼女士、王亚东先生、 ...

中国人民保险集团股份有限公司（以下简称"本公司"）于 2025 年 4 月 29 日召开 2025 年第一次临时股东大会，选举贾若先生为本公 司第五届董事会独立董事。贾若先生担任本公司独立董事的任期，自 股东大会审议通过其担任公司独立董事且其独立董事任职资格获得 国家金融监督管理总局核准之日起算。 近日，本公司收到《国家金融监督管理总局关于贾若中国人民保 险集团股份有限公司独立董事任职资格的批复》（金复〔2025〕755 号）。根据上述批复，国家金融监督管理总局已核准贾若先生担任本 公司独立董事的任职资格。贾先生担任本公司独立董事的任职已生效， 且根据本公司 2025 年 6 月 27 日第五届董事会第十次会议决议，贾先 生担任董事会关联交易控制委员会主任委员和风险管理与消费者权 益保护委员会、审计委员会委员任职同时生效。贾若先生的简历请见 本公司于 2025 年 4 月 8 日在上海证券交易所网站发布的《中国人民 保险集团股份有限公司 2025 年第一次临时股东大会会议资料》。 证券代码：601319 证券简称：中国人保 公告编号：临 2025-043 自贾若先生任职之日起，邵善波先生不再担任本公司独立董事 ...

Core Viewpoint - China People's Insurance Group has announced the approval of Jia Ruo as an independent non-executive director by the National Financial Supervision Administration, effective immediately, while Shao Shanbo has simultaneously resigned from the position [1] Group 1 - Jia Ruo's appointment as an independent non-executive director has been officially approved [1] - The resignation of Shao Shanbo from the position of independent non-executive director has also taken effect [1]

Group 1 - The core point of the article is the appointment of Mr. Jia Ruo as an independent non-executive director of China People's Insurance Group, which has been approved by the National Financial Regulatory Administration [1] - The appointment of Mr. Jia Ruo has become effective simultaneously with the resignation of Mr. Shao Shanbo as an independent non-executive director [1]

Core Viewpoint - The insurance sector experienced a decline of 0.38% on December 31, with China Life Insurance leading the losses, while the overall market showed mixed results with the Shanghai Composite Index slightly up by 0.09% and the Shenzhen Component Index down by 0.58% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3968.84, reflecting a 0.09% increase [1] - The Shenzhen Component Index closed at 13525.02, showing a 0.58% decrease [1] - The insurance sector's individual stock performance varied, with China Life Insurance down by 0.15% and China Ping An down by 0.58% [1] Group 2: Stock Data - China Pacific Insurance (601601) closed at 41.91 with no change in price [1] - China Life Insurance (601628) closed at 45.50, down 0.15% with a trading volume of 98,400 shares and a transaction value of 448 million [1] - New China Life Insurance (601336) closed at 69.70, down 0.54% with a trading volume of 107,300 shares and a transaction value of 750 million [1] - China Ping An (601318) closed at 68.40, down 0.58% with a trading volume of 458,100 shares and a transaction value of 3.142 billion [1] - China Reinsurance (601319) closed at 8.95, down 0.89% with a trading volume of 508,900 shares and a transaction value of 458 million [1] Group 3: Fund Flow Analysis - The insurance sector saw a net outflow of 500 million from main funds, while retail investors contributed a net inflow of 305 million [1] - The detailed fund flow for individual stocks showed significant outflows for China Life Insurance and China Pacific Insurance, while retail investors showed positive net inflows for several stocks [2] - China Life Insurance had a main fund net inflow of 4.56 million, while China Reinsurance experienced a net outflow of 32.41 million from main funds [2]

Group 1 - The insurance sector is expected to deepen its transformation and maintain a recovery trend in fundamentals through 2026 [4][7] - In 2025, the insurance sector outperformed the market with a cumulative increase of 27.0%, surpassing the CSI 300 index by 8.8 percentage points, driven by strong growth in new business value (NBV) and improved investment returns [5][10] - The life insurance segment is seeing a stabilization in agent workforce and positive growth in new policies, supported by bank insurance and improved NBV margins [5][20] Group 2 - The property insurance segment is experiencing a slowdown in premium growth but is optimizing its business structure, with a focus on non-auto insurance [22] - The investment side of the insurance companies is benefiting from a rising equity market, with a projected increase in total investment returns and net profits expected to rise by 33.5% year-on-year for the first three quarters [5][7] - The high savings preference among residents and the reduction in bank deposit rates are expected to make participating insurance products with a guaranteed return of 1.75% more competitive in the market [7][8] Group 3 - The life insurance sector is projected to see continued growth in new business value, driven by the popularity of participating insurance products and the effective management of costs through the "reporting and operation integration" strategy [5][20] - The property insurance sector is expected to maintain its favorable conditions, with the "reporting and operation integration" policy further optimizing the combined ratio (COR) [5][22] - Investment strategies focusing on high dividend yields are anticipated to provide a safety net for net investment income, contributing to profit stability [7][8]

格隆汇12月31日丨中国人民保险集团(01339.HK)发布公告，贾若就任公司独立非执行董事的资格已获国 家金融监督管理总局核准。上述委任已生效，而邵善波退任公司独立非执行董事亦同时生效。 ...

中国人民保险集团股份有限公司 章程 《中国人民保险集团股份有限公司章程》 | 序号 | 章程制定 | 决议时间 | 会议名称 | 国务院保险监督管 理机构批准文号 | | --- | --- | --- | --- | --- | | 1 | 章程制定 | 2012 年 5 月 14 日 | 2012 年第三次股 东大会 | 保监发改〔2012〕 579 号（2012 年 5 月 16 日） | | 2 | 第一次修订 | 2012 年 6 月 14 日 | 2012 年第四次股 东大会 | 保监发改〔2012〕 997 号（2012 年 8 月 21 日） 保监发改〔2012〕 | | 3 | 第二次修订 | 2012 年 11 月 21 日 | 2012 年第五次股 东大会 | 1423 号（2012 年 12 月 12 日）及保监发 改〔2013〕296 号 （2013 年 3 月 29 | | 4 | 第三次修订 | 2013 年 12 月 27 日 | 2013 年第二次临 时股东大会 | 日） 保监许可〔2014〕 134 号（2014 年 2 月 12 日） | | 5 | 第四次修订 | 20 ...